# A Double-Blind, Controlled Study of Aripiprazole in Co-Morbid Schizophrenia and Cocaine Dependence

> **NCT00737256** · PHASE2 · UNKNOWN · sponsor: **Paul Saenger** · enrollment: 44 (estimated)

## Conditions studied

- Schizophrenia
- Cocaine Dependence

## Interventions

- **DRUG:** Aripiprazole
- **DRUG:** Perphenazine

## Key facts

- **NCT ID:** NCT00737256
- **Lead sponsor:** Paul Saenger
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-08
- **Primary completion:** 2013-05
- **Final completion:** 2014-05
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2012-09-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00737256

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00737256, "A Double-Blind, Controlled Study of Aripiprazole in Co-Morbid Schizophrenia and Cocaine Dependence". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00737256. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*